In pancreatic neuroendocrine neoplasms, the IL6/Stat3 pathway upregulates Nrp1 (42), and AhR signaling has been shown to inhibit IL-6 (43–45). This evidence concerns the gene IL6 and pancreatic neuroendocrine neoplasm.